The Foundation recently consulted with external experts from the fields of HIV and drug harm reduction to learn how they were able to tilt the needle away from moral panic, toward evidence-informed policies. Drawing on decades of experience, they told us that success requires a concerted effort to harness not just data, but emotion and personal narratives.
What is harm reduction?
Since at least the early 1970s, the world has waged a “War on Drugs.” From the start, the watch word in the trenches of that war was prohibition (“Just say no”). Front-line weapons included stigma, incarceration, and, in some countries, execution of drug users. Harm reduction, by contrast, involves policies and programs that aim to reduce adverse health, social, and economic consequences of legal and illegal psychoactive drugs without necessarily reducing consumption.
Harm reduction strategies are taken for granted in our everyday lives. For example, we use seatbelts to minimize driving danger, soft padding to make playgrounds safer, shark cages (for “shark week”), and sunscreen to reduce the risk of skin cancer. We do not prohibit driving, playing and beach-going.
Harm reduction is inherently noncoercive and respectful of users, making it an ethical alternative to prohibition. A central tenet of HIV and drug harm reduction is that it is not possible (and often not desirable) to prevent certain behaviors, especially those associated with pleasure. As one expert told us, it is “better to aim for and achieve sub-optimal goals than to aim for and fail to achieve utopian goals.”
History & lessons learned
Harm reduction for people who use drugs has a long history. Opium was provided to addicts during the colonial era in Asia; and morphine could be obtained by prescription for opioid-dependent individuals in early 20th Century Britain. In the 1960s, the United States introduced methadone maintenance programs, spurring stiff opposition from professionals and the public.
Critics argued that drug harm reduction programs would recruit naïve new users, including young people, and that they could be a “gateway” to more dangerous drugs. The naysayers were rarely swayed by scientific evidence contradicting these assumptions. Opposition ultimately subsided following the explosion of HIV infections among injecting drug users during the 1980s and 1990s.
Today, most public health authorities and policy makers embrace the full armamentarium of drug and HIV harm reduction interventions, including condoms, safe needle exchange sites, drug consumption rooms, and substitution therapies (e.g., methadone and buprenorphine). But this change in public opinion was not driven by facts alone. It required strategic communications that appealed to emotions.
Public support for drug harm reduction only increased when advocates succeeded in humanizing people who use drugs. Advocates organized users and relevant stakeholders first, enlisted journalists second, and only then targeted key policymakers. HIV and drug harm reduction advocates also pursued more traditional advocacy strategies, including lobbying, paid and earned media, mobilizing artists and celebrities, social marketing, and direct action (e.g., marches and disruptions).
Since harm reduction now lies at the center of the public health response to HIV/AIDS and drug use, one might assume that health authorities would also embrace tobacco harm reduction. Unfortunately, they do not.
The Foundation has listened to external experts and will embrace the following guiding principles to promote tobacco harm reduction. First, all messages must be evidence-based. Second, messaging must include the authentic voices, and emphasize the humanity, of stigmatized smokers and ex-smokers.
Key recommendations from our external consultations include the need to support consumer voices, and to develop media that promote human stories and counteract misinformation. The experts we engaged with underscored a need to look “beyond the usual suspects” (e.g., to lawyers and patient advocacy groups), and to ensure that vulnerable and low-income populations benefit from safer alternatives.
External experts also noted that human rights and justice lie at the core of harm reduction. One of the most impactful positions taken by people who are HIV positive and/or who use drugs, as well as people with disabilities, is this simple demand: “Nothing About Us Without Us.” We believe this is just as relevant for anyone caught in the crossfire of the war on tobacco harm reduction.
Mission is to eliminate smoking worldwide by supporting cessation & harm reduction #research, and transitioning tobacco #farmers to alternative livelihoods.
In his latest blog, Derek Yach notes, “In 2020, we must not only acknowledge that smoking persists as a pressing global health threat, but also adapt our tactics to address the ways in which this threat has evolved.” #AccelerateTransformation http://bit.ly/37ci1ma
How insurers can profit while helping people to quit smoking
The Foundation is collaborating with the insurance industry to raise awareness about how insurers can help end smoking. This could create shared value that will benefit smokers, insurers and society as a whole. #endsmoking, #insuranceindustry. http://bit.ly/2sZCifK
David Janazzo, CFO and VP of #IndustryTransformation examines how Tobacco Free Portfolios, Bloomberg STOP’s Global Tobacco Industry Interference Index, and FSFW’s Tobacco Transformation Index are complementary. http://bit.ly/2QTQfoI
New ASH & Cancer Research UK report:
"Local authorities which do not currently provide e-cigarette starter packs as part of their cessation offer should consider doing so to give local smokers the best possible chance to quit."
"Only" 11% do so now.
Sign up with your email address to receive news and updates